Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,579.34
(
1.28%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
100.51
(
3.84%
)
Bitcoin
70,205.00
(
-0.98%
)
News Focus
News Focus
Post# of 257273
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 252182

Friday, 06/14/2024 9:46:34 PM

Friday, June 14, 2024 9:46:34 PM

Post# of 257273
Re: PFE’s CD47 program

Clinicaltrials.gov shows these active phase-2 or phase-1/2 trials for PFE’s CD47 agent, Maplirpacept (PF-07901801):

https://www.clinicaltrials.gov/study/NCT05626322
https://www.clinicaltrials.gov/study/NCT05896163

Maplirpacept was also listed in the slide set for PFE’s Feb 2024 Oncology Day (https://investors.pfizer.com/files/doc_downloads/2024/02/29/Pfizer-Oncology-Innovation-Day-Presentation_FINAL.pdf , #18), although there were no further details.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today